ArticleScientific reports2025
Monolaurin inhibits antibiotic-resistant Staphylococcus aureus in patients with atopic dermatitis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.Frontiers in immunology · 2025Trial
- Postbiotic metabolites fromExperimental and therapeutic medicine · 2026Article
- Emerging therapeutic drug targets in amino acid and protein biosynthesis pathways against ESKAPE and non-ESKAPE pathogens: a comprehensive review.Archives of microbiology · 2026Review
- Intranasal phage therapy overcomes antibody neutralization challenges in pulmonary Pseudomonas aeruginosa infections.Archives of microbiology · 2025Article
- Medium-Chain Triglyceride Emulsion with Phytocannabinoids and Monolaurin Improves Growth and Survival in Suckling Piglets.Animals : an open access journal from MDPI · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Frequent use of antibiotics increases the incidence of antimicrobial-resistant Staphylococcus aureus in atopic dermatitis (AD), which prompts the search for new treatments. Monolaurin is a chemical byproduct found in coconut oil and has anti-bacterial properties. This study aimed to investigate the inhibitory effect of monolaurin on antimicrobial-resistant S. aureus. Thirty children and thirty adults diagnosed with AD were recruited and swabbed at three different sites: lesion, non-lesion, and nasal mucosa. Methicillin resistance and high-level mupirocin resistance in S. aureus were identified using mecA and mupA PCR, respectively, whilst fusidic acid resistance were detected by fusA gene sequencing. The broth microdilution method and tetrazolium bromide assays were used for monolaurin susceptibility and cellular cytotoxicity, respectively. We show that S. aureus was frequently isolated from lesions of both children and adults with AD. One isolate of methicillin-resistant S. aureus (MRSA) harboring mecA, one isolate of mupirocin-resistant S. aureus harboring mupA, and four isolates of fusidic acid-resistant S. aureus with novel point mutations of fusA were found in the children group. In silico molecular docking showed that these mutants interacted weakly with fusidic acid, explaining the mechanism of drug resistance. Monolaurin inhibited these antimicrobial-resistant S. aureus isolates with a minimal inhibitory concentration of 2 µg/mL without cytotoxicity to cultured epidermal and dermal cells. These data show that monolaurin could potentially be used to inhibit antimicrobial-resistant S. aureus in AD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.